Brief: Gensight Biologics FY Net Loss Narrows To EUR 28.6 Mln

Gensight Biologics SA

08/04/2022 06:38

April 8 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * CASH RUNWAY CONFIRMED TO EARLY Q1 2023
    * OPERATING LOSS WAS CONTAINED IN 2021 AMOUNTING TO EUR 28.1
MILLION COMPARED TO EUR 24.9 MILLION IN 2020
    * RAMP UP OF SALES & MARKETING ACTIONS AND INVESTMENTS TO
DRIVE
COMMERCIAL LAUNCH OF LUMEVOQ(®) IN EUROPE IN 2023
    * OPERATING INCOME INCREASED BY 3.6% TO EUR 7.7 MILLION IN
2021
FROM EUR 7.4 MILLION IN 2020
    * CASH AND CASH EQUIVALENTS TOTALED EUR 44.3 MILLION AS OF
DECEMBER 31, 2021, COMPARED TO EUR 37.9 MILLION AS OF DECEMBER
31, 2020
    * FY NET LOSS EUR 28.6 MILLION VERSUS LOSS OF EUR 34.0
MILLION
YEAR AGO
    * WITH A CURRENT CASH RUNWAY TO EARLY Q1 2023, WE ARE
ASSESSING
SEVERAL FINANCING OPTIONS, NON OR AS LITTLE DILUTIVE AS
POSSIBLE, TO ENSURE A SUCCESSFUL EUROPEAN COMMERCIAL LAUNCH OF
LUMEVOQ IN 2023

Source text for Eikon:  ID:nBw4nk2Tda 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))